<DOC>
	<DOCNO>NCT02927366</DOCNO>
	<brief_summary>This non-confirmatory , randomize , subject investigator blind , placebo control study QCC374 PAH patient . The study 2 part . In Part 1 , initial safety cohort , 8 subject randomize 6:2 ratio start dose 0.03 mg b.i.d.. In Part 2 , ~ 30 subject randomize 2:1 ratio , plan start dose 0.06 mg b.i.d.. In Parts , subject up-titrated first two week study 0.12 mg b.i.d , maximum tolerate dose ( MTD ) individual MTD 0.12 mg b.i.d . first two week study . The treatment duration 16 week .</brief_summary>
	<brief_title>Safety , Pharmacokinetics Efficacy Study QCC374 PAH Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>Male female patient 18 year age old symptomatic PAH . Subjects PAH belong one follow subgroup Updated Clinical Classification Group 1 ( Nice , 2013 ) : Idiopathic PAH familial PAH PAH associate connective tissue disease , congenital heart disease ( surgically repair least 12 month prior screen ) drug toxin induce ( example , anorexigen use ) . Subjects must persistent symptom due PAH despite therapy least one follow PAH medication : endothelin receptor antagonist , asoluble guanylate cyclase stimulator phosphodiesterase inhibitor . The subject ' PAH medication regimen , typical medication include calcium channel blocker , endothelin receptor antagonist , soluble guanylate cyclase stimulators and/or phosphodiesterase inhibitor , must use stable dose frequency least 12 week screen visit screen period . Diagnosis PAH establish accord standard criterion screen visit : Resting mean pulmonary arterial pressure &gt; 25 mmHg . PVR &gt; 240 dyne s/cm5 . Pulmonary capillary wedge pressure leave ventricular end diastolic pressure &lt; 15 mmHg PVR &gt; 400 dyne s/cm5 time baseline right heart catheterization ( RHC ) ( RHC complete within one month screen visit , result may use inclusion ) . 6minute walk distance great 150 meter Screening . This distance must confirm second 6MWT prior randomization . The value second 6MWD within Â± 15 % value obtain Screening . Subjects clinically unstable right heart failure within last three month ( New York Heart Association ( NYHA ) Class IV ) . Subjects PAH associate portal hypertension , Human Immunodeficiency Virus ( HIV ) infection unrepaired congenital systemic pulmonary shunt Subjects receive scheduled receive longterm treatment epoprostenol prostacyclin within three month prior screen visit screen period . Hypotensive subject ( systemic systolic blood pressure &lt; 85 mmHg ) Subjects history leave sided heart disease , chronic left side heart failure , congenital acquire valvular disease and/or pulmonary venous hypertension . Subjects significant obstructive ( forced expiratory volume one second [ FEV1 ] /forced vital capacity [ FVC ] &lt; 70 % predict ) restrictive ( total lung capacity &lt; 70 % predict ) lung disease screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Pulmonary hypertension ( PH ) ,</keyword>
	<keyword>Increase blood pressure pulmonary artery</keyword>
	<keyword>Increased blood pressure pulmonary vein</keyword>
	<keyword>Increased blood pressure lung vasculature</keyword>
	<keyword>Shortness breath</keyword>
	<keyword>Dizziness</keyword>
	<keyword>Fainting</keyword>
	<keyword>Leg swell</keyword>
	<keyword>Cough</keyword>
	<keyword>Angina pector</keyword>
</DOC>